Abstract
The lungs of smokers are exposed to the toxic substances of cigarette smoke, but only 10-20% of them will develop chronic obstructive pulmonary disease (COPD). For COPD to develop, cigarette smoke has to bypass or overwhelm the host front lines of defence, i.e. the respiratory tract mucosal epithelium, which serves as an effective physical barrier and the innate immune system, which provides an immediate, yet non-specific response. In this review, we will describe briefly how cigarette smoke succeeds in damaging the physical barrier of mucosal epithelium and the innate immune system, and how it induces effector mechanisms of the adaptive immune system, which are particularly cytotoxic to the host. We will also discuss the role of other stimuli with immunogenic potential, such role of pathogens which colonize or evade the lungs of COPD patients and of self tissue antigens, which may lead to autoimmune disease when there is chronic inflammation. Although the primary mechanism(s) of undesirable innate and adaptive immune responses in COPD are still a matter of debate, it is currently accepted that they are the root cause of COPD.
Keywords: Chronic obstructive pulmonary disease, cigarette smoke, pathogenesis, innate, adaptive, epithelium, inflammation, protease, oxidative stress, lymphocyte, dendritic cell, autoimmune
Current Drug Targets
Title: Mechanisms of Altered Cell Immunity and Cytotoxicity in COPD
Volume: 12 Issue: 4
Author(s): M. Tsoumakidou, I. Tsiligianni and N. Tzanakis
Affiliation:
Keywords: Chronic obstructive pulmonary disease, cigarette smoke, pathogenesis, innate, adaptive, epithelium, inflammation, protease, oxidative stress, lymphocyte, dendritic cell, autoimmune
Abstract: The lungs of smokers are exposed to the toxic substances of cigarette smoke, but only 10-20% of them will develop chronic obstructive pulmonary disease (COPD). For COPD to develop, cigarette smoke has to bypass or overwhelm the host front lines of defence, i.e. the respiratory tract mucosal epithelium, which serves as an effective physical barrier and the innate immune system, which provides an immediate, yet non-specific response. In this review, we will describe briefly how cigarette smoke succeeds in damaging the physical barrier of mucosal epithelium and the innate immune system, and how it induces effector mechanisms of the adaptive immune system, which are particularly cytotoxic to the host. We will also discuss the role of other stimuli with immunogenic potential, such role of pathogens which colonize or evade the lungs of COPD patients and of self tissue antigens, which may lead to autoimmune disease when there is chronic inflammation. Although the primary mechanism(s) of undesirable innate and adaptive immune responses in COPD are still a matter of debate, it is currently accepted that they are the root cause of COPD.
Export Options
About this article
Cite this article as:
Tsoumakidou M., Tsiligianni I. and Tzanakis N., Mechanisms of Altered Cell Immunity and Cytotoxicity in COPD, Current Drug Targets 2011; 12 (4) . https://dx.doi.org/10.2174/138945011794751546
DOI https://dx.doi.org/10.2174/138945011794751546 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of Antioxidant Polyphenols on TNF-Alpha-Related Diseases
Current Topics in Medicinal Chemistry Multiple Sclerosis Therapy Monitoring Based on Gene Expression
Current Pharmaceutical Design Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab
Current Drug Targets From Cannabis to Endocannabinoids in Multiple Sclerosis: A Paradigm of Central Nervous System Autoimmune Diseases
Current Drug Targets - CNS & Neurological Disorders Dendritic Cell Homeostasis in the Regulation of Self-Reactivity
Current Pharmaceutical Design Randomized Controlled Trials in Prevention of PostSurgical Recurrence in Crohn’s Disease
Reviews on Recent Clinical Trials The Neuropeptides VIP / PACAP and T Cells: Inhibitors or Activators?
Current Pharmaceutical Design Ulcerative Colitis: Pathogenesis
Current Drug Targets Assessment of Endothelial Function by Positron Emission Tomography
Current Cardiology Reviews B Cell Depletion with Rituximab in Graves Disease and Associated Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Impact and Therapeutic Potential of PPARs in Alzheimers Disease
Current Neuropharmacology Recent Applications of Chemiluminescence Assays in Clinical Immunology
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Toll-Like Receptors and Innate Immunity: Potential Drug Targets for Treatment of Infectious, Inflammatory, and Autoimmune Diseases (Executive Editor: Emilio Jirillo)]
Current Pharmaceutical Design Advances in the Treatment of Autoimmune Diseases; Cellular Activity, Type-1/Type-2 Cytokine Secretion Patterns and their Modulation by Therapeutic Peptides
Current Medicinal Chemistry Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents A Quantitative Structure-Activity Relationship Study on Some Series of Potassium Channel Blockers
Medicinal Chemistry Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Emerging Role of Regulatory T Cells in Gene Transfer
Current Gene Therapy Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism